Latest Lung Imaging News

Cyclopharm’s Technegas has been recognised as the preferred ventilation agent in a pivotal draft US lung imaging guideline, signalling a major boost for its adoption in American clinical practice.

Cyclopharm Limited confirms its insurer has assumed responsibility for defending the company in ongoing legal proceedings initiated by 4DMedical Limited. This development marks a significant step in managing the dispute’s financial and operational risks.

4DMedical Limited has raised AU$150 million to accelerate the commercial rollout of its FDA-cleared CT, VQ lung imaging technology in the US, leveraging a strategic partnership with Philips. This funding aims to expand adoption across major medical centres and government healthcare programs.

4DMedical Limited has raised $150 million through a well-supported institutional placement to accelerate the commercialisation of its innovative lung imaging product CT – VQ™ in the US market. The capital raise comes with minimal dilution and increased insider confidence.

Cyclopharm secures a landmark deal with Lucile Packard Children’s Hospital Stanford to introduce Technegas, marking the first dedicated children’s hospital in the US to adopt this advanced lung imaging technology.

UC San Diego Health has begun clinical use of 4DMedical’s CT – VQ™, marking the fourth leading US academic medical centre to adopt this innovative lung imaging technology since FDA clearance. This milestone underscores 4DMedical’s rapid commercial traction and growing influence in respiratory diagnostics.

Cyclopharm Limited has secured regulatory approval for its Technegas lung imaging technology in Colombia, marking its presence in 67 countries worldwide. This milestone aligns strategically with the upcoming global nuclear medicine congress in Cartagena.

4DMedical has gained Canadian regulatory approval for its innovative CT – VQ™ ventilation-perfusion imaging technology, enabling immediate commercial rollout through Philips and expanding its North American footprint.

4DMedical secures a key clinical adoption milestone as the University of Miami begins using its CT – VQ™ respiratory imaging technology, following Stanford’s lead. Meanwhile, Lahey Hospital inks a two-year deal for IQ-UIP™, underscoring growing traction in US academic medical centers.

4DMedical has expanded its partnership with Philips, securing a US$10 million order commitment to distribute its CT – VQ™ lung imaging technology across North America, aiming to transform pulmonary diagnostics.

Cyclopharm Limited reaffirms its ambitious target of 250–300 US Technegas installations by late 2026, driven by FDA approval, CMS reimbursement, and a growing pipeline of healthcare sites. The company reports record half-year revenue growth, signaling strong momentum in the expanding lung imaging market.

4DMedical has responded to ASX queries over its FY2025 financial report, clarifying assumptions behind intangible asset valuations and addressing the auditor’s qualified opinion.